298. 遺伝性膵炎 Hereditary pancreatitis Clinical trials / Disease details
臨床試験数 : 95 / 薬物数 : 148 - (DrugBank : 51) / 標的遺伝子数 : 53 - 標的パスウェイ数 : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05069597 (ClinicalTrials.gov) | October 14, 2021 | 27/9/2021 | Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon | A Phase 4 Study to Assess Symptoms of Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon® (Pancrelipase) With an Alternate Source of Active Pharmaceutical Ingredient | Cystic Fibrosis;Chronic Pancreatitis | Drug: CREON | AbbVie | NULL | Recruiting | 18 Years | N/A | All | 30 | Phase 4 | United States |
| 2 | NCT04949828 (ClinicalTrials.gov) | September 16, 2021 | 21/6/2021 | Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms | Observational Study Assessing for Effect of CREON on Symptoms of Exocrine Pancreatic Insufficiency (EPI) in Patients With EPI Due to Chronic Pancreatitis (CP) | Chronic Pancreatitis | Drug: CREON | AbbVie | NULL | Recruiting | 18 Years | N/A | All | 90 | United States | |
| 3 | NCT04315311 (ClinicalTrials.gov) | May 6, 2020 | 18/3/2020 | Study Of Effects Of Oral CREON Capsules In Adult Participants With Exocrine Pancreatic Insufficiency Not Due To Cystic Fibrosis, Chronic Pancreatitis, Pancreatectomy, Or Pancreatic Cancer | A Phase 4 Open-Label Single-Arm Study To Evaluate The Use Of CREON In Subjects With EPI Due To Etiologies Other Than Cystic Fibrosis, Chronic Pancreatitis, Pancreatectomy, Or Pancreatic Cancer | Exocrine Pancreatic Insufficiency (EPI) | Drug: CREON | AbbVie | NULL | Withdrawn | 18 Years | N/A | All | 0 | Phase 4 | United States |
| 4 | NCT02849704 (ClinicalTrials.gov) | October 13, 2016 | 27/7/2016 | Fat Malabsorption in Chronic Pancreatitis | Diagnosing Pancreatic-Based Malabsorption in Patients With Chronic Pancreatitis | Chronic Pancreatitis | Drug: Creon36™ | Children's Hospital of Philadelphia | AbbVie;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);Phoenix Indian Medical Center | Completed | 30 Years | 70 Years | All | 48 | Phase 2 | United States |
| 5 | EUCTR2015-002570-20-ES (EUCTR) | 25/02/2016 | 18/04/2016 | Optimizing treatment of maldigestion in patients with chronic pancreatitis | Open label, randomized, crossover clinical trial to evaluate the efficacy of increasing doses of pancreatic enzymes against inhibition of acid gastric secretion in patients with exocrine pancreatic insufficiency secondary to chronic pancreatitis | Patients diagnosed of chronic pancreatitis with pancreatic exocrine insufficiency under pancreatic enzyme replacement therapy;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Trade Name: Kreon 25000 Product Name: Creon 25000 Product Code: PL 00512/0150 | Department of gastroenterology. University Hospital of Santiago | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Spain | ||||
| 6 | NCT00705978 (ClinicalTrials.gov) | June 2008 | 26/6/2008 | Creon 40,000 for Treatment of PEI (Pancreatic Exocrine Insufficiency) Due to Chronic Pancreatitis | A One Week Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study With Creon 40,000 MMS in Subjects With Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis, Followed by an Open-Label Long-Term Extension | Pancreatic Insufficiency | Drug: Pancreatin;Drug: Placebo | Abbott Products | Quintiles, Datamap | Completed | 18 Years | N/A | Both | 62 | Phase 3 | India |
| 7 | EUCTR2007-004004-12-BG (EUCTR) | 28/02/2008 | 05/02/2008 | A STUDY TO INVESTIGATE THE EFFECT OF PANCRELIPASE DELAYED RELEASE CAPSULES ON MALDIGESTION IN PATIENTS WITH EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CHRONIC PANCREATITIS AND PANCREATECTOMY | A STUDY TO INVESTIGATE THE EFFECT OF PANCRELIPASE DELAYED RELEASE CAPSULES ON MALDIGESTION IN PATIENTS WITH EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CHRONIC PANCREATITIS AND PANCREATECTOMY | Pancreatic enzyme replacement therapy is the cornerstone of nutritional management of pancreatic exocrine insufficiency (PEI) due to e.g. cystic fibrosis, chronic pancreatitis, partial or complete pancreatectomy or gastrectomy. Without pancreatic enzyme replacement the patients suffer from severe symptoms of maldigestion as manifested by steatorrhea, abdominal pain, body weight loss etc. MedDRA version: 9.1;Level: LLT;Classification code 10009093;Term: Chronic pancreatitis MedDRA version: 9.1;Classification code 10033596;Term: Pancreatectomy | Trade Name: Creon 10000 Product Name: Pancrelipase Delayed Release Capsule Other descriptive name: Pancrelipase/Pancreas Powder Trade Name: Creon 25000 Product Name: Pancrelipase Delayed Release Capsule Other descriptive name: Pancrelipase/Pancreas Powder | Solvay Pharmaceuticals GmbH | NULL | Not Recruiting | Female: yes Male: yes | 52 | Bulgaria | |||
| 8 | NCT01154608 (ClinicalTrials.gov) | April 2005 | 30/6/2010 | Effect of Enzyme Therapy on Protein Metabolism in Chronic Pancreatitis | Pancreatitis | Drug: Creon;Other: No enzyme therapy | Institut National de la Recherche Agronomique | National Research Agency, France;Solvay Pharmaceuticals | Completed | 18 Years | N/A | Both | 11 | N/A | France | |
| 9 | NCT00957151 (ClinicalTrials.gov) | April 2004 | 11/8/2009 | Evaluation of the Digestive and Metabolic Utilisation of Dietary Protein in Patients With Chronic Pancreatitis | Evaluation of the Digestive and Metabolic Utilisation of Dietary Protein in Patients With Chronic Pancreatitis | Chronic Pancreatitis | Drug: Creon | Hospital Avicenne | Solvay Pharmaceuticals | Completed | 18 Years | 65 Years | Both | 12 | Phase 4 | France |